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Abstract
The ATM/ATR DNA damage checkpoint functions in the maintenance of genetic stability and some missense variants of the
ATM gene have been shown to confer a moderate increased risk of prostate cancer. However, whether inactivation of this
checkpoint contributes directly to prostate specific cancer predisposition is still unknown. Here, we show that exposure of
non-malignant prostate epithelial cells (HPr-1AR) to androgen led to activation of the ATM/ATR DNA damage response and
induction of cellular senescence. Notably, knockdown of the ATM gene expression in HPr-1AR cells can promote androgen-
induced TMPRSS2: ERG rearrangement, a prostate-specific chromosome translocation frequently found in prostate cancer
cells. Intriguingly, unlike the non-malignant prostate epithelial cells, the ATM/ATR DNA damage checkpoint appears to be
defective in prostate cancer cells, since androgen treatment only induced a partial activation of the DNA damage response.
This mechanism appears to preserve androgen induced autophosphorylation of ATM and phosphorylation of H2AX, lesion
processing and repair pathway yet restrain ATM/CHK1/CHK2 and p53 signaling pathway. Our findings demonstrate that
ATM/ATR inactivation is a crucial step in promoting androgen-induced genomic instability and prostate carcinogenesis.
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Introduction
Prostate cancer is currently the most commonly diagnosed male
cancer in Western countries. When the cancer reaches the
metastatic stage, the only frontline treatment available is androgen
ablation therapy. Unfortunately, more than 70% of the patients
will experience recurrence due to the development of a hormone-
refractory stage. Currently, there is no effective second-line
treatment available for patients at this stage. Therefore, it is
important to understand the mechanisms responsible for prostate
carcinogenesis and to identify a better prognostic marker for
prostate cancer patients.
Similar to other cancers, genetic instabilities such as chromo-
some translocation are frequently detected in prostate cancer cells
and are believed to play an initiating role in disease development.
One of the prostate cancer-specific chromosome translocation is
the fusion of TMPRSS2 and ERG genes, which has been reported
in 60–70% of prostate cancer tissues [1]. Other commonly
detected translocations include fusion of TMPRSS2: ETV genes
[2] and SLC45A3: ELK4 [3]. Although how these fusion genes
may contribute to prostate carcinogenesis are still largely
unknown, fusion transcripts such as TMPRSS2: ERG has been
shown to drive prostate neoplastic development. The chromo-
somal rearrangement also occurs as an early event and continues
to be expressed in metastatic and castration-resistant disease [2],
suggesting that these products may at least be involved in disease
progression.
Recently the male sex hormone androgen has been demon-
strated to promote the recruitment of androgen receptor (AR) and
topoisomerase II beta (TOP2B) to genomic breakpoints induced at
androgen responsive genes including TMPRSS2: ERG fusion, the
most common fusion detected in prostate cancer [4]. In a separate
study, liganded-AR was also found to recruit endonuclease and
deaminase at juxtaposed translocation loci and promote site-
specific DNA double-stranded break [5]. More importantly, both
studies demonstrated that transient androgen treatment resulted in
induction of TMPRSS2: ERG fusion in prostate cancer cells,
suggesting that androgen may play an important role in prostate
cancer predisposition. In a more recent study, prolong androgen
treatment was found to induce TMPRSS2: ERG fusion in the non-
malignant prostate epithelial cells [6]. Interestingly, in the study by
Lin et al, a transient androgen treatment was unable to induce
TMPRSS2: ERG fusion in non-malignant prostate epithelial cells
even in the presence of genotoxic stress, indicating the presence of
repair mechanism in non-malignant prostate epithelial that
suppress genetic instability, which has been abrogated in prostate
cancer cells [5].
Genetic instabilities such as chromosome translocation trigger
the activation of the ATM/ATR DNA damage checkpoint to
arrest cell cycle and facilitate DNA repair [7,8]. ATM is mainly
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activated by DNA double-strand breaks (DSBs) [9], while ATR
responds to replication stress, although it is now recognized that
the ATM pathway can also activate downstream components of
the ATR arm following induction of DSBs in S-and G2 phases
of cell cycle [10,11]. Once activated ATM/ATR phosphorylate
downstream effector proteins to initiate cell cycle checkpoints,
and facilitate DNA repair through phosphorylating a number of
its downstream targets such as checkpoint kinase 1 (Chk1),
checkpoint kinase 2 (Chk2) and histone H2AX [12,13,14].
Interestingly, ATM has been reported to be highly activated in
prostatic intraneoplasia (PIN), which is regarded as a precursor
of prostate cancer [15]. Furthermore, some missense variants of
the ATM gene have been shown to confer a moderate
increased risk of prostate cancer. These observations suggest
that the ATM DNA damage checkpoint acts as a barrier to
initiation of prostate cancer, possibly through detecting and
repairing the genetic instability that occurs during early stage of
cancer development. Nonetheless, whether inactivation of this
checkpoint plays a direct role in prostate cancer predisposition
is still unknown.
In the present study, we provide evidence for the first time that
androgen-induced activation of the ATM DNA damage check-
point as well as the induction of cellular senescence in non-
tumorigenic prostate epithelial cell (HPr-1 AR). More importantly,
in the presence of androgen, inactivation of the ATM DNA
damage checkpoint led to the induction of TMPRSS2/ERG
fusion transcript in HPr-1 AR cells. Despite the fact that androgen
treatment also induced ATM phosphorylation in prostate cancer
cells (LNCaP), we were unable to detect any changes in the
phosphorylation level of Chk1/2 or H2AX proteins, suggesting
that the ATM DNA damage checkpoint can only be partially
activated in prostate cancer cells. These results suggested that the
ATM/ATR DNA damage checkpoint may play a crucial role in
suppressing androgen-induced chromosome translocation in pros-
tate epithelial cells, and inactivation of this checkpoint may
facilitate androgen-induced genetic instability and prostate carci-
nogenesis.
Results
Androgen Activates ATM/ATR DNA Damage Checkpoint
in HPr-1 AR Cells
Androgen induces prostate cancer-specific translocations of
TMPRSS2: ERG in prostate cancer cells but not in non-malignant
prostate epithelial cells [5]. We hypothesize that this may due to
the activation of the ATM/ATR DNA damage checkpoint in the
non-malignant cells, which may help in suppressing the androgen-
induced chromosome instability. To test this hypothesis, an
immortalized non-malignant prostate epithelial cell line was used
as a model. The HPr-1 cells were first stably transfected with AR
by using the lentiviral gene delivery system. As shown in Figure 1A,
the AR protein expression level in the HPr-1 AR is comparable to
that in LNCaP cells. The HPr-1 AR cells were then exposed to
synthetic androgen analog R1881 for 24 hours, and the expression
and phosphorylation levels of the DNA damage checkpoint
proteins were determined. As shown in Figure 1B, phosphoryla-
tion level of ATM (Ser 1981) and ATR (Ser 426) was upregulated
after R1881 treatment, demonstrating the activation of both ATM
and ATR by androgen treatment. Phosphorylations of ATM/
ATR downstream targets such as Chk1 (Ser 317) and Chk2 (Thr
68) were also observed upon androgen treatment. More impor-
tantly, the level of c-H2AX, a sensitive and well-known DNA
damage marker, was also increased after the treatment. This was
further confirmed by immunofluorescence staining revealing an
increase in the percentage of cells displaying .10 c-H2AX foci in
androgen-treated compared to non-treated HPr-1 AR cells
(Figure 1C). These findings suggest that androgen treatment
may induce DNA damage in non-malignant prostate epithelial
cells, which led to activation of the ATM-ATR DNA damage
checkpoint pathway.
ATM/ATR DNA damage checkpoint activation has previously
been shown to induce cellular senescence, a major protective
mechanisms against genetic instability [16]. Meanwhile, androgen
treatment was also found to induce the expression of the
senescence marker p16 (Fig. 1B). To investigate if androgen-
induced ATM/ATR activation also triggers cellular senescence,
HPr-1 AR cells were treated with R1881 or vehicle for 6 days and
stained for senescence associated b-galactosidase (b-gal). As shown
in Figure 1D, the percentage of b-gal positive cells (appear as blue-
green) was significantly induced by R1881 treatment, indicating
that HPr-1 AR cells undergo cellular senescence when exposed to
androgen treatment.
Knockdown of ATM Promotes Androgen-induced
Chromosome Translocation in HPr-1 AR Cells
Next, we asked if inactivation of the ATM/ATR DNA damage
checkpoint may facilitate androgen-induced TMPRSS2: ERG
fusion. We then knockdown the expression of either the ATM
or ATR gene in HPr-1 AR cells by transiently transfecting the cells
with ATM siRNA (siATM) or ATR siRNA (siATR). As shown in
Figure 2A, transfection of siATM and siATR effectively knock-
down levels of ATM and ATR protein, respectively, in HPr-1 AR
cells as compared to the scramble control (siCon). Examination of
cH2AX expression revealed that knockdown of ATM or ATR
both suppressed the induction of cH2AX by androgen treatment
(Figure 2B), suggesting that the androgen-induced DNA damage
response was significantly suppressed by ATM/ATR knockdown.
Consistent with the previous findings [4,5], short-term treatment
of the non-malignant prostate epithelial cells (HPr-1 AR) with
androgen did not induce TMPRSS2: ERG fusion transcript
(Figure 2C).More importantly, we were able to detect a TMPRSS2:
ERG fusion transcript (Figure 2C) in the ATM-deficient HPr-1 AR
cells treated with androgen. However, transient knockdown of
ATR was able to induce the same fusion transcript, confirming
that the ATM DNA damage checkpoint is acting as a surveillance
system to guard against the androgen-induced chromosome
translocation.
Androgen Induces Partial Activation of the ATM DNA
Damage Checkpoint in LNCaP Cells
The fact that androgen treatment alone can induce TMPRSS2:
ERG fusion in the prostate cancer, LNCaP, cell line suggests that
these cells may contain a detective ATM/ATR DNA damage
checkpoint. We therefore tested if androgen exposed LNCaP cells
also activates the same DNA damage response pathway as
reported above for HPr-1 AR (non-malignant prostate epithelial)
cells. Phosphorylation levels of the DNA damage checkpoint
proteins were examined in LNCaP cells after 24 hours of androgen
(R1881) treatment. Similar to HPr-1 AR cells, ATM phosphor-
ylation level was significantly increased when LNCaP cells were
exposed to R1881 (Figure 3A). Notably, LNCaP cells showed
constitutive phosphorylation of ATR (Ser 428), Chk2 (Thr 68) and
Chk1 (Ser 317) and these were all decreased after the androgen
(R1881) treatment. Meanwhile, cH2AX level remained un-
changed during the treatment. These results suggested that
androgen-induced DNA damage response pathway is partially
impaired in LNCaP cells.
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Although androgen treatment did not induce the activation of
the ATM/ATR downstream proteins, we were still able to detect
the G1 cell cycle arrest of LNCaP cells after the treatment
(Figure 3B). To investigate if the cell cycle arrest is the
consequence of the partial activation of the ATM/ATR DNA
damage checkpoint, stable LNCaP sublines with ATM (shATM)
and ATR (shATR) knockdown were generated by lentiviral gene
delivery system. Western blotting results in Figure 3C showed that
the ATM and ATR were effectively knockdown in shATM and
shATR transfectants when compared to the control (shCon)
transfectants. We next analyzed the effect of androgen treatment
(R1881) on cell cycle profile of these transfectants. Similar to the
parental cells, shCon or shATR transfected LNCaP-cells under-
went G1 arrest after treatment with R1881 (Figure 3D). Moreover,
the treatment did also result in suppression of the number of viable
cells in both LNCaP-shCon and shATR transfectants (Figure S1).
However, ATM-deficient LNCaP (LNCaP-shATM) cells failed to
significantly alter the percentage of cells in G1 phase of cell cycle
after R1881 treatment (Figure 3D). Consistent with the cell cycle
analysis, R1881 also failed to affect the viable cell number in
ATM-deficient LNCaP cells (Figure S1). These findings illustrate
that androgen induces G1 cell cycle arrest through an ATM-
dependent and ATR-independent mechanism.
Differential Regulation of the ATM/ATR Downstream
Targets in LNCaP cells after Androgen Treatment
Given that master regulators of the G1 arrest are p53 and
CDC25A, two of the major downstream effectors of the ATM/
ATR DNA damage checkpoint, this prompted us to examine the
regulation of this pathway in LNCaP cells. p53 is phosphorylated
by Chk1/2 in response to DNA damage, which leads to its
stabilization [17,18,19]. Consistent with the decrease in phos-
phorylation of Chk1 and Chk2, p53 protein level was also found to
be downregulated by androgen treatment in LNCaP cells
(Figure 4A). The fact that p53 mRNA level remain constant after
the treatment while degradation of p53 protein was accelerated
(Figure 4C) indicated that the downregulation of p53 by androgen
is due to destabilization of the protein, possibly due to the decrease
in Chk1/2 activity. This is further confirmed by treatment of
LNCaP cells with the proteasome inhibitor (MG132), which
completely abolished the effect of androgen on p53 proteins
(Figure 4D).
Next, we examined the effect of androgen on CDC25A, which
is phosphorylated by Chk1/2 in response to DNA damage
[20,21]. Unlike p53, phosphorylation of CDC25A is known to
destabilize the protein, leading to induction of cell cycle arrest.
Intriguingly, R1881 was found to downregulate CDC25A in a
dose dependent manner (Figure 5A), even though the phosphor-
ylation levels of Chk1/2, indicative of activation status, were
suppressed by the treatment, suggesting that androgen downreg-
ulates CDC25A in a Chk1/2 independent manner. Meanwhile,
both CDC25A mRNA and promoter activity were not affected by
R1881 treatment (Figure 5A & Figure S2), suggesting that the
decrease in protein expression is mediated through post-transcrip-
tional mechanism. This is confirmed by determining the
degradation profiles of CDC25A protein in androgen-treated
and -untreated LNCaP cells (Figure 5B). Moreover, treatment of
LNCaP cells with the proteasome inhibitor (MG132) completely
abolished the effect of androgen on CDC25A proteins (Figure 5C).
These results further suggest that androgen downregulates
CDC25A through a proteasome-mediated protein degradation
pathway.
To investigate if androgen regulates p53 and CDC25A protein
levels through the ATM/ATR DNA damage checkpoint, we
tested the effect of androgen on p53 and CDC25A expression in
shATM and shATR transfectants when compared to the control
(shCon). As shown in Figure 5D, knockdown of ATM, but not
ATR, partially recovered the CDC25A protein expression in
LNCaP cells, suggesting that downregulation of CDC25A by
androgen requires the activation of ATM. Consistent with these
findings even the transient knockdown of ATM (siATM), but not
ATR in LNCaP cells completely abolished the effect of androgen
on CDC25A protein expression (Figure S3). However, neither
stable nor transient knockdown of ATM or ATR abolish the effect
of androgen on p53 level. These results suggested that androgen
destabilized CDC25A, but not p53 protein through activating the
ATM-dependent DNA damage response pathway that leads to G1
arrest in prostate cancer cells.
Discussion
In the present study, we reported that androgen activates the
ATM/ATR DNA damage response and induces cellular senes-
cence in non-malignant prostate epithelial cells. Furthermore,
inactivation of ATM/ATR led to accumulation of the androgen-
induced chromosome translocation. Our results demonstrate for
the first time the cooperative effect of androgen and DNA damage
response inactivation in prostate cancer predisposition.
Androgen has recently been shown to induce prostate specific
chromosomal translocation in LNCaP cells concomitantly treated
with genotoxic stress. Intriguingly, the same treatment was unable
to induce any detectable chromosomal translocation in non-
malignant prostate epithelial cells [5], although a prolonged
exposure to androgen was found to induce the TMPRSS2/ERG
fusion transcript [6]. A possible reason for this disparity could be
the differences in the integrity of the DNA damage response
between normal and cancer cells. In fact, in our study the
treatment of HPr-1AR cells with androgen were found to result in
activation of both ATM and ATR, leading to the phosphorylation
of Chk1/2 and the induction of cH2AX (Figure 1A). However, in
LNCaP cells, the same treatment only induced the phosphoryla-
tion of ATM (Figure 3A) without activation of downstream targets
suggesting that these cells may have a defective androgen-induced
activation of DNA damage response. In fact, we observed
constitutive phosphorylation of ATR and CHK1 and CHK2
which was substantially decreased upon exposure to androgen.
The failure of androgen to induce cH2AX in LNCaP cells
(Figure 3A) further highlighted the presence of defective androgen-
induced DNA damage response in prostate cancer cells.
Figure 1. Effect of androgen on the activation of ATM/ATR DNA damage checkpoint in HPr-1 AR cells. (A) Expression of AR in HPr-1 cells
were compared to that in LNCaP cells by Western blotting. (B) Androgen activates ATM/ATR DNA damage checkpoint in HPr-1 AR cells. Levels of
phosphor-ATM (Ser 1981), phosphor-ATR (Ser 428), phosphor-Chk1 (Ser 317), phosphor-Chk2 (Thr 68), cH2AX and p16 in HPr-1 AR cells after 24 hours
of R1881 treatment. (C) Androgen induces cH2AX foci formation in HPr-1AR cells. cH2AX foci was detected with immunofluorescent staining and
counted under microscope. Result was presented as percentage of cH2AX positive cells. (D) Androgen induces cellular senescence in HPr-1 AR cell.
Cells were treated with different dosages of R1881 for 6 days and stained with senescence-associated b-galactosidase for 16 hours. The images were
captured under 2006magnification. The percentage of positively stained cells was calculated. The standard deviation of the means was used as error
bars. p,0.05 was considered statistically significant as determined by student-t test.
doi:10.1371/journal.pone.0051108.g001
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More importantly, we showed that non-malignant prostate
epithelial cells (HPr-1AR) become susceptible to androgen-
induced chromosomal translocation after transient knockdown of
ATM (Figure 2C), further demonstrating the crucial role of the
ATM DNA damage response in the maintenance of chromosome
stability in non-malignant cells. Indeed, some missense variants of
ATM gene mutation have previously been shown to confer
increased risk of prostate cancer [22,23]. In the study by Angele
et al, one out of the five ATM variants (P1054R) was found to
associate with increased risk of prostate cancer development [22].
Figure 2. Knockdown of ATM/ATR promotes androgen-induced chromosome translocation in HPr-1 AR cells. (A) Knockdown of the
ATM and ATR expression in HPr-1 AR cells. Cells were transiently transfected with scramble control siRNA (siCon), siATM and siATR for 48 hours and
were harvested for Western blotting analysis. B) Androgen-induced cH2AX was suppressed in ATM/ATR deficient HPr-1 AR cells. Cells were transiently
transfected with siCon, siATM and siATR and exposed to R1881 for 24 hours. Level of cH2AX was examined by Western blotting. C) Androgen induces
chromosome translocation of TMPRSS2: ERG in ATM deficient HPr-1 AR cells. Cells were transiently transfected with scramble control siRNA (siCon),
siRNA targeting ATM (siATM) and that targeting ATR (siATR) and treated with/without R1881 for 24 hours and harvested for RNA extraction. cDNA
was then synthesized and the mRNA level of TMPRSS2:ERG fusion gene was analyzed by nested PCR. Note that TMPRSS2: ERG gene fusion transcript
can only be detected in ATM-deficient HPr-1 AR cells that treated with androgen.
doi:10.1371/journal.pone.0051108.g002
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In another study, the same ATM variant was also reported to
cause a twofold increase in the risk of developing prostate cancer
[23]. Thus, our findings may help to understand the association
between ATM mutation and prostate cancer development.
It is interesting to note that HPr-1AR cells treated with
androgen undergo cellular senescence eventually (Figure 1D).
Cellular senescence, a process of irreversible arrest of cell division,
is one of the safeguard mechanisms to prevent cancer formation.
Previous reports have shown that senescence can be induced by
DNA damage in tumor cells through an ATM/ATR dependent
mechanism [24,25,26]. In addition, cells entering senescence
display increased cH2AX foci [25,27,28]. The induction of
cellular senescence and cH2AX foci in HPr-1 AR cells by
androgen treatment suggests that androgen may induce DNA
damage, leading to activation of ATM/ATR DNA damage
response. Indeed, by inactivating the ATM/ATR DNA damage
response pathway, we were able to mimic the response of LNCaP
cells to androgen treatment in HPr-1AR cells, as evidenced by the
induction of TMPRSS2/ERG fusion transcript and the lack of
cH2AX induction after androgen treatment (Figure 2B & C).
These results indicate the potential defects in mounting optimal
response to androgen-induced DNA damage in prostate cancer
cells, which may in-turn explain the escape of prostate cancer cells
from cellular senescence.
Unlike HPr-1AR cells, LNCaP cells treated with androgen was
found to undergo cell cycle arrest (Figure 3B), which is consistent
with previous study [29]. However, we found that the G1 arrest
induced by androgen is in fact associated with degradation of the
tyrosine phosphatase CDC25A (Figure 5A–C), which is one of the
cell cycle proteins regulated by the ATM-dependent DNA damage
response [30,31]. Consistent with this, knockdown of ATM not
only recovered the CDC25A protein level, but also completely
abolished the effect of androgen on G1 arrest (Figure 3D and
Figure 5D). In regards to ATM functioning to regulate CDC25A
levels in LNCaP cells treated with androgen, the mechanism is
unlikely to be Chk1/2 dependent given that phosphorylation of
both is decreased after androgen exposure (Figure 3A). However,
it is noteworthy that, recently, Raf-1/ERK pathway, activated in
LNCaP by androgen treatment [32], was found to phosphorylate
CDC25A at the Chk1/2 phosphorylation site and to induce its
degradation [33]. Since Raf-1/ERK has been shown to be
required for ATM DNA damage checkpoint functioning [34], it is
thus possible that in the absence of Chk1/2 activation, androgen
exposure induces ATM mediated CDC25A degradation through
Raf-1/ERK activation.
In summary, we have demonstrated the effect of androgen on
the activation of ATM/ATR DNA damage response and the
consequent induction of senescence in non-malignant prostate
epithelial cells. Notably, this pathway is partially impaired in
prostate cancer cells. Collectively, these findings establish that
inactivation of ATM pathway is a crucial step in promoting
androgen-induced TMPSS2: ERG chromosome translocation and
the consequent genomic instability and prostate carcinogenesis.
Considering the role of androgen in the pathology of prostate
cancer, our findings may provide a possible linkage between
androgen, genomic instability and prostate carcinogenesis.
Materials and Methods
Cell Culture
Human prostate cancer cell line LNCaP was obtained from
American Type Culture Collection (Rockville, MD). Prostate
epithelial cell line HPr-1 was was described in the previous study
[35]. LNCaP was maintained in medium RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 2% penicillin-streptomycin (P/
S) (Invitrogen, Carlsbad, CA) and 5% fetal bovine serum (FBS)
(Invitrogen, Carlsbad, CA). HPr-1 was maintained in keratinocyte-
serum free medium (Invitrogen, Carlsbad, CA) supplemented with
1% P/S. All cell types were kept at 37uC, 5% CO2. For
experiments, the cells were incubated in RPMI medium supple-
mented with 5% (v/v) charcoal-dextran-treated fetal bovine serum
(CSFBS) for 24 hrs before androgen supplementation. The
synthetic androgen methyltrienolone (R1881) (Perkin-Elmzer,
Waltham, MA) was dissolved in absolute ethanol at a concentra-
tion of 100 mM. The proteasome inhibitor, MG132, and
cycloheximide (CHX) (Calbiochem, San Diego, CA) were
dissolved in DMSO at concentration of 10 mM and 100 mg/ml
respectively.
siRNAs Transient Transfection
The siGENOME non-targeting siRNA pool #1 (siCon), ON-
TARGET plus SMARTpool siRNA human ATR (siATR) and
ON-TARGET plus SMARTpool siRNA human ATM (siATM)
were purchased from Dharmacon, Chicago, IL. They were
transfected into the cells using LipofectamineTM 2000 reagent
(Invitrogen, Carlsbad, CA) following the manufacturer’s instruc-
tion. Twenty-four hours after transfection, cells were either lysed
for western blotting analysis or treated with R1881 for 72 hr
before lysed for mRNA extraction and RT-PCR analysis.
Generation of Stable Knockdown Transfectants
The HPr-1 AR overexpressing transfectants (HPr-1 AR) was
generated by using pLenti6-AR expression vector. LNCaP ATM
(LNCaP shATMi) and ATR (LNCaP shATRi) knockdown
transfectants were generated by using pLKO.1 ATM shRNA
and ATR shRNA expression vectors respectively. The MissionTM
non-target shRNA control vector SHC002 (Sigma, St. Louis, MO)
was used for the generation of the corresponding control.
Lentivirus were generated and used for infecting HPr-1 and
LNCaP cells with protocol described in our previous studies [36].
Western Blotting
Western blotting was carried out as described previously [37].
The antibodies were purchased from following suppliers:
CDC25A, AR, p16 and b-actin (Santa Cruz, CA, USA);
Phospho-ATM (Ser1981), Phospho-ATR (Ser 428), Phospho-
Chk1 (Ser317), Phospho-Chk2 (Thr68), ATM and ATR (Cell
Signaling Technology Inc); phospho- Histone H2A.X (Ser 139)
Figure 3. Effect of androgen on activation of ATM/ATR DNA damage checkpoint in LNCaP cells. (A) Levels of phosphor-ATM (Ser 1981),
phosphor-ATR (Ser 428), phosphor-Chk2 (Thr 68), phosphor-Chk1 (Ser317) and cH2AX in LNCaP cells after 24 hrs of R1881 treatment. (B) Androgen
induces G1 arrest in LNCaP cells. LNCaP cells supplemented with R1881 alone (upper panel) or together with nocodazole (lower panel) for 24 hours
were harvested and fixed for cell cycle analysis using flow cytometry. The percentages represent cell population at different phases of the cell cycle.
(C) Protein expression of ATM and ATR in LNCaP-shCon, shATM and shATR transfectants were examined by Western blotting. (D) Androgen fails to
induce G1 arrest in shATM transfectants. shCon, shATM and shATR transfectants were treated with different doses of R1881 for 24 hours and cells
were fixed for flow cytometry analysis. Table showed the percentage change of G1 phase and S phase LNCaP cells after supplemented with 1 nM
R1881 for 24 hours. Androgen fails to suppress cell proliferation in shATM LNcaP transfectant.
doi:10.1371/journal.pone.0051108.g003
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(Millipore Corporation, Billerica, MA); p53 (Dakocytomation,
Glostrup, Denmark).
Dual Luciferase Reporter Assay
pGL3-CDC25A-Luc was a gift from Professor Daniel DiMaio
(Yale University School of Medicine, New Haven, Connecticut,
U.S.). LNCaP cells were plated in 12-wells plates at 20%
confluency and were transfected with pGL3-CDC25A-Luc and
the internal control pRL-TK-Luc. The transfectants were then
treated with methyltnenolone (R1881) for another 24 hrs. Cells
were then lysed and assayed for luciferase activity using Dual-
LuciferaseH Reporter Assay System (Promega, Madison, WI)
following manufacturer’s instruction. The pRL-TK-Luc was used
as an internal control and the experiment was performed in
triplicate.
3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium
Bromide (MTT) Assay
Cells were grown in 96-well plate with 100 ml culture medium.
At indicated time point, 10 ml of MTT labeling reagent (5 mg/ml,
in PBS) was added to each wells and incubated for 4 hours at
37uC. After 4-hour incubation, the formazan crystals formed were
dissolved with 200 ml of DMSO (Sigma, St. Louis, MO) and
incubated for 5 minutes at 37uC. After that, absorbance at 570 nm
was measured using Labsystem multiscan microplate reader
(Merck Eurolab, Dietikon, Schweiz). 100 ml culture medium was
set as blank control and experiment was performed in triplicate.
Immunofluorescent Staining
Cells were seeded on 8-well chamber slide and fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) and washed
once with PBS. The cells were then permeablilized with 1%
Triton X-100 in PBS. Cells were blocked with 1% BSA in PBS for
20 minutes and incubated with anti-phospho-Histone H2A.X
(Ser139) (c-H2AX) antibody (1:200, Milipore, Billerica, MA) for 2
hours at room temperature. Cell were washed thrice with PBS and
incubated with relevant fluorescein-labeled secondary antibody.
Cellular DNA content was counterstained with 0.5 mg/ml 49 6-
diamidino-2-phenylindole (DAPI). Fluorescent signals were visu-
alized with Carl Zeiss Imager Z1 microscope with Apotome slider
(Carl Zeiss, Inc., Thornwood, NY) and photographed using
Axiovision software. At least 250 cells were counted under 2006
magnification for each experiment and cells containing .10
fluorescent foci was counted as positively stained. The standard
deviation of the means for at least three independent experiment
was used as error bars. P,0.05 was considered statistically
significant as determined by student-t test.
Senescence-associated b-galatocidase Staining (SA b-gal)
Cells were seeded on 12-well plate at 20% confluency. After 6
days treatment, cells were washed once with 500 ml 16PBS
(pH 6.0) and fixed with 16 fixative solution (2% formaldehyde
and 0.2% glutaraldehyde in PBS). After the fixation, cells were
then washed with 16PBS twice and stained with the Senescence-
associated b-galatocidase staining kit (Cell signaling, Beverly, MA).
Positive cells were counted under microscope. At least 500 cells
were counted from 3 random fields and the percentage of
positively stained cells was calculated. The standard deviation of
the means was used as error bars. P,0.05 was considered
statistically significant as determined by student-t test.
Reverse Transcriptase- polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated using TRIZOLH reagent (Invitrogen,
Carlsbad, CA) following the manufacturer’s instructions. Two
micrograms of cDNA was synthesized by using SuperScriptTM
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad,
CA) and PCR was carried out with GeneAmpH PCR System 9700
(Applied Biosystems, Foster City, CA). The CDC25A primers
sequences are 59-GCC TCT CGT GGC AGG GCA GTC-39 and
59-CAT CAC CTG GCC TGA GGA ATC-39; p53 primers
sequences are 59-TCA GAT CCT AGC GTC GAG CCC-39 and
59-GGG TGT GGA ATC AAC CCA CAG-39; GAPDH primers
sequences are 59-ACC ACA GTC CAT GCC ATC AC-39 and
59-TCC ACC ACC CTG TTG CTG TA-39. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression was examined as
an internal control.
TMPRSS2-ERG fusion product was detected with a two-step
nested PCR. First PCR was performed with primers described by
Lin et al [5], while the nested PCR was performed with the
primers described by Clark et al [38] with expected size of
,300 bp. PCR products were resolved in agarose gel and the
image was captured with a gel documentation system.
Cell Cycle Analysis
Cells were plated in 5% FBS culture medium at 20%
confluency and incubated in 5% CSFBS culture medium for 24
hours before R1881 treatment. Where indicated, nocodazole was
added into the medium 8 hrs after the addition of R1881. The
cells were then harvested and fixed in ice cold 70% ethanol. The
cells were then washed with phosphate-buffered saline (PBS)
before incubation with propidium iodide (50 mg/ml) and RNase
(1 mg/ml) for 30 mins. Cell cycle analysis was performed on a flow
cytometer EPICS profile analyzer and analyzed using the ModFit
LT2.0 software (Coulter, Miami, FL).
Determination of Half-life of Proteins
The procedures for determination of protein half-life were as
described previously [39]. Cells were treated with 1 nM R1881
and collected after treatment with protein synthesis inhibitor
cycloheximide (50 ug/ml) for the indicated time point. Cells were
then lysed for Western blotting with anti-CDC25A and anti-p53
antibodies. The band intensity of the Western blotting result was
measured by gel documentation system with the reading
Figure 4. Differential effect of androgen on the regulation of ATM/ATR downstream targets in LNCaP cells. (A) Androgen down
regulates p53 protein expression in LNCaP cells. LNCaP cells were treated with R1881 for 24 hours and harvested for Western blotting analysis on p53
protein expression (Left panel). p53 mRNA levels in androgen-treated LNCaP cells were examined by RT-PCR and GAPDH expression level was used as
a loading control (Right panel). (B) Androgen promotes p53 protein degradation in LNCaP cells. Degradation profile of p53 protein in LNCaP cells with
or without R1881 (1 nM) treatment was examined by blocking protein synthesis with CHX (50 mg/ml). p53 protein level was measured at the
indicated time points by Western blotting. Signal intensity of the Western blotting result was measured by gel documentation system and the
reading was normalized as percentage to that of the initial p53 level (level at time= 0). (C) Log10 of the percentage was plotted against time and the
half-life of the p53 protein was calculated as the time corresponding to the log10 of 50%. (D) Androgen fails to down regulate p53 in the presence of
proteasome inhibitor. LNCaP cells were treated with 1 nM R1881 for 24 hrs. At 16 hrs of R1881 treatment, 2 mM of the proteasome inhibitor (MG132)
was added. At the end of the treatment, cells were lysed for western blotting analysis using p53 antibody.
doi:10.1371/journal.pone.0051108.g004
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Figure 5. Androgen downregulates CDC25A protein in an ATM dependent manner. (A) LNCaP cells were treated with R1881 for 24 hours
and harvested for Western blotting analysis and RT-PCR on CDC25A protein and mRNA expression. b-actin (WB) and GAPDH (RT-PCR) were used as a
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normalized as percentage of the initial CDC25A level (level at
time= 0). The percentages of CDC25A and p53 level were then
plotted against time in Log scale. Slope was calculated from the
plot and was used to generate the half-life (t = 1/2) of the CDC25A
and p53 protein, which is the time required for degradation of
50% of the initial protein.
Supporting Information
Figure S1 shCon, shATM and shATR transfectants were
treated with different doses of R1881 for 5 days and
MTT assay was performed. The experiment was performed
in triplicates and the mean and standard deviation were
calculated.
(TIF)
Figure S2 CDC25A promoter activity was determined in
androgen-treated LNCaP cells by luciferase reporter
assay. TK promoter activity was used as the internal control.
(TIF)
Figure S3 LNCaP cells were transient transfected with
non-targeting siRNA (siCon) and siRNA targeting ATM
(siATM). Cells were then treated with R1881 for 24 hours and
then harvested for Western blotting analysis.
(TIF)
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